
For adults with episodic cluster headache,
Emgality 300 mg is the first medication approved to reduce the number of weekly cluster headache attacks that occur during a cycle
Select Safety Information
Do not use Emgality if you are allergic to galcanezumab-gnlm or any of the ingredients in Emgality.
In a study, people taking Emgality 300 mg had*

With Emgality, they experienced an average of 9 fewer weekly attacks over the first 3 weeks vs 5 fewer weekly attacks for those taking placebo.

Weekly cluster headache attacks were cut in half or more for 71% of people 3 weeks after taking their first dose of Emgality vs 53% for placebo.
*People in a study had an average of 18 cluster headache attacks each week during their cluster cycle.
Select Safety Information
Emgality may cause allergic reactions, such as itching, rash, hives, and trouble breathing. Allergic reactions can happen days after using Emgality. Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms, which may be part of an allergic reaction:
- swelling of your face, mouth, tongue, or throat
- trouble breathing
Fewer cluster headache attacks means more moments to celebrate.
Ask your doctor if Emgality 300 mg could be right for you to help reduce the frequency of your cluster headache attacks
Understanding Emgality
Emgality was specifically developed to bind to CGRP, a substance in the brain that may play a key role in episodic cluster headache, and block its binding to the receptor.
CGRP=calcitonin gene-related peptide.

Find out more about Emgality 300 mg from a real patient with episodic cluster headache
Find out more